| CYDY Stock | | | USD 0.11 0.01 8.33% |
Chairman
Dr. Denis R. Burger, Ph.D., is Director of CytoDyn Inc. Consideration of his nomination was recommended to the Nominating and Governance Committee by the Companys Chief Executive Officer. He is also currently a director of Lorus Therapeutics, Inc., a cancer therapeutics company listed on the TSX, and serves on its audit committee. Dr. Burger cofounded Trinity Biotech PLC, a NASDAQ listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995, and is currently lead independent director. Until March 2007, he was Chairman and Chief Executive Officer of AVI Biopharma Inc., a NASDAQ listed RNA therapeutics company. He was also a cofounder of Epitope Inc., serving as its Chairman from 1981 to 1990. Dr. Burger previously held a professorship in the Department of Microbiology and Immunology and Surgery at the Oregon Health and Sciences University in Portland. Dr. Burger received his undergraduate degree in Bacteriology and Immunology from the University of California, Berkeley and his MS and Ph.D. degrees in Microbiology and Immunology from the University of Arizona. Dr. Burger brings significant biotechnology company experience and operational expertise to our Board, as well as a local presence for in person consultations with management. . since 2014.
| Age | 79 |
| Tenure | 10 years |
| Phone | 360 980 8524 |
| Web | https://www.cytodyn.com |
Burger received his undergraduate degree in Bacteriology and Immunology from the University of California in Berkeley and his MS and Ph.D. degrees in Microbiology and Immunology from the University of Arizona.
Cytodyn Management Efficiency
The company has return on total asset
(ROA) of
(1.4819) % which means that it has lost $1.4819 on every $100 spent on assets. This is way below average. Cytodyn's management efficiency ratios could be used to measure how well Cytodyn manages its routine affairs as well as how well it operates its assets and liabilities.
Cytodyn currently holds 37.35
M in liabilities. Cytodyn has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cytodyn until it has trouble settling it off, either with new capital or with free cash flow. So, Cytodyn's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytodyn sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytodyn to invest in growth at high rates of return. When we think about Cytodyn's use of debt, we should always consider it together with cash and equity.
CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people. Cytodyn [CYDY] is traded as part of a regulated electronic over-the-counter service offered by the NASD.
Management Performance
Cytodyn Leadership Team
Elected by the shareholders, the Cytodyn's board of directors comprises two types of representatives: Cytodyn inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytodyn. The board's role is to monitor Cytodyn's management team and ensure that shareholders' interests are well served. Cytodyn's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytodyn's outside directors are responsible for providing unbiased perspectives on the board's policies.
Cytodyn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cytodyn a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Cytodyn OTC Stock Analysis
When running Cytodyn's price analysis, check to
measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to
predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.